Norgine appoints global market access director

Norgine has announced the instatement of experienced medical sector professional Peter Conway as its new global market access director.

Mr Conway assumed his new role within the company's commercial division on April 8th 2013 and has been tasked with ensuring all appropriate patients are able to access Norgine's marketed and development projects now and in the future.

He brings extensive experience in managing national and international market access functions to the role, having previously been employed by Glaxo Wellcome, Wyeth and – most recently – Grunenthal.

Norgine's product portfolio is focused on addressing unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and critical and supportive care, with key brands including Movicol, Moviprep, Klean-Prep, Xifaxan and Oramorph.

The firm also has a range of new drugs in various stages of clinical development and manufactures the majority of its own products in the UK and France.

It launched Targaxan 550 – a new treatment for overt hepatic encephalopathy developed in collaboration with Alfa Wassermann – in Britain earlier this year.